Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDKN1A | P38936 | 1/20 | 0.55 |
| ▸ | BRAF | P15056 | 15/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5819971 | 0.87 | CDKN1A (0.69) | CDKN1ABRAFMAPK13PIM1MAPK9 | |
| SCHEMBL7398130 | 0.86 | CDKN1A (0.56) | CDKN1ABRAFMAPK13PIM1MAPK9 | |
| SCHEMBL6071504 | 0.86 | CDKN1A (0.75) | CDKN1ABRAFMAPK13PIM1EPHA2 | |
| SCHEMBL10736365 | 0.86 | CDKN1A (0.69) | CDKN1ABRAFMAPK13PIM1MAPK9 | |
| SCHEMBL5820151 | 0.85 | CDKN1A (0.74) | CDKN1ABRAFMAPK13PIM1MAPK9 | |
| SCHEMBL5946458 | 0.85 | CDKN1A (0.74) | CDKN1ABRAFMAPK13PIM1 | |
| SCHEMBL5946435 | 0.85 | CDKN1A (0.74) | CDKN1ABRAFMAPK13PIM1 | |
| SCHEMBL10731164 | 0.84 | CDKN1A (0.56) | CDKN1ABRAFMAPK13PIM1MAPK9 | |
| SCHEMBL5819815 | 0.84 | CDKN1A (0.51) | CDKN1ABRAFMAPK13PIM1MAPK9 | |
| SCHEMBL7402900 | 0.83 | CDKN1A (0.56) | CDKN1ABRAFMAPK13PIM1MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063784-A1 | Method of using substituted pyrazolo [1,5-a] pyrimidines | WYETH | 2006-03-23 | — | — | US | claimed |
| WO-2006033795-A2 | SUBSTITUTED PYRAZOLO [1, 5-A] PYRIMIDINES FOR INHIBITING ABNORMAL CELL GROWTH | WYETH (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063784-A1 | Method of using substituted pyrazolo [1,5-a] pyrimidines | WYETH | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063784-A1 | Method of using substituted pyrazolo [1,5-a] pyrimidines | TYMP, DPYD, TYMS | CDKN1A 89/4885BRAF 523/4885MAPK13 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.